ImmuCell Corporation - Common Stock (ICCC)
Frequently Asked Questions About ImmuCell Corporation - Common Stock (ICCC)
Are there any recent developments at ImmuCell?
Recent developments at ImmuCell have included the introduction of new product formulations and clinical studies aimed at validating the effectiveness of its existing products. The company frequently updates stakeholders via press releases and earnings calls to communicate its advancements and business performance.
Has ImmuCell received any awards or recognitions?
Yes, ImmuCell has received various awards and recognitions for its commitment to innovation and excellence in the biotechnology sector. These accolades often highlight the effectiveness and impact of its products in improving animal health, reinforcing its reputation as a leader in the field.
How can customers purchase ImmuCell products?
Customers can purchase ImmuCell products through veterinary suppliers, distributors, and direct sales channels. The company maintains relationships with its clients to ensure that its innovative solutions are readily available to those in the agricultural sector.
How does ImmuCell contribute to sustainability in agriculture?
ImmuCell contributes to sustainability in agriculture by providing products that promote better animal health and productivity. By improving livestock health, the company helps farmers achieve higher production efficiency, reducing waste and resource consumption associated with livestock management.
How does ImmuCell ensure product quality?
ImmuCell ensures product quality through rigorous testing, compliance with industry standards, and adherence to regulatory requirements. The company follows Good Manufacturing Practices (GMP) to maintain the highest quality in its product formulations and to assure customers of safety and efficacy.
How does ImmuCell impact animal health?
ImmuCell has a significant impact on animal health by providing solutions that prevent common health issues in livestock. Products like 'First Defense' offer vital immunoglobulin supplementation for newborn calves, reducing the incidence of disease and improving overall herd health and productivity.
Is ImmuCell Corporation publicly traded?
Yes, ImmuCell Corporation is publicly traded on the Nasdaq stock exchange under the ticker symbol 'ICCC'. The company's stock is available for purchase by investors, allowing them to support and be a part of its growth in the biotechnology sector.
What challenges does ImmuCell face?
Like many companies in biotechnology, ImmuCell faces challenges such as regulatory hurdles, competition from other firms in animal health, and the need for ongoing innovation to meet customer demands. Managing these challenges effectively is crucial for the company’s continued success and market growth.
What does ImmuCell Corporation do?
ImmuCell Corporation is a biotechnology company focused on developing and commercializing innovative products for the healthcare of cattle and other livestock. The company's primary aim is to enhance animal health and productivity through immunological-based solutions, especially concentrating on products that aid in preventing and treating common issues like mastitis in dairy cows.
What is ImmuCell's flagship product?
ImmuCell's flagship product is named 'First Defense', an innovative product designed to provide passive immunity to newborn calves by delivering immunoglobulin through oral administration. This product is utilized within hours of birth to help ensure the health and survival of calves, making it essential for livestock producers.
What is the growth strategy of ImmuCell Corporation?
ImmuCell's growth strategy includes continual investment in research and development to expand its product line, as well as strategic partnerships and collaborations within the agricultural industry. The company seeks to broaden its market reach and enhance customer engagement through educational initiatives and outreach.
What is the mission statement of ImmuCell Corporation?
The mission statement of ImmuCell Corporation is to develop and commercialize innovative healthcare products for livestock that enhance animal health and productivity. The company is dedicated to improving the welfare of animals through scientific advancements and customer-focused solutions.
What is the vision of ImmuCell Corporation?
ImmuCell Corporation's vision is to become a leader in the field of animal health by providing innovative products that ensure animal welfare and promote efficient animal production. The company aims to improve the health outcomes of livestock, contributing to a more sustainable agricultural industry.
What markets does ImmuCell target?
ImmuCell targets the livestock sector, particularly dairy and beef cattle markets. The company's products are aimed at veterinary professionals, dairy farmers, and livestock producers, addressing issues of animal health and welfare while enhancing agricultural productivity.
What plans does ImmuCell have for future product development?
ImmuCell has plans for future product development that focus on expanding its portfolio of immunological health products. The company is committed to ongoing research and development initiatives designed to address emerging needs within the livestock sector, ensuring its offerings remain relevant and beneficial.
What research and development efforts does ImmuCell undertake?
ImmuCell invests significantly in research and development to innovate and improve its product offerings. The company focuses on immunological therapies and products that enhance the health and productivity of livestock, aiming to bring new solutions to market that meet the evolving needs of cattle producers.
When was ImmuCell Corporation founded?
ImmuCell Corporation was founded in 1982. Since its inception, the company has focused on research and development efforts to deliver effective health products for livestock, helping to improve the overall well-being of animals in the agricultural sector.
Where is ImmuCell Corporation located?
ImmuCell Corporation is based in Portland, Maine. The company's headquarters houses its research, development, and administrative operations, with a strong commitment to serving the needs of the agricultural community in the U.S. and globally.
Who are the key executives at ImmuCell?
The key executives at ImmuCell include President and CEO Michael Brigham, who has played a substantial role in the growth of the company, as well as other essential personnel in positions like Chief Financial Officer and Vice President of Operations. Together, they guide the company’s strategic direction and product development.
What is the current price of ImmuCell Corporation - Common Stock?
The current price of ImmuCell Corporation - Common Stock is 10.05
When was ImmuCell Corporation - Common Stock last traded?
The last trade of ImmuCell Corporation - Common Stock was at 4:00 pm EDT on August 14th, 2026
What is the market capitalization of ImmuCell Corporation - Common Stock?
The market capitalization of ImmuCell Corporation - Common Stock is 77.81M
How many shares of ImmuCell Corporation - Common Stock are outstanding?
ImmuCell Corporation - Common Stock has 7.74M shares outstanding.